Table 1 Clinicopathological characteristics of all enrolled ESCC patients

Sex, n (%)

0.087^#

 Male

45 (76.3%)

88 (63.8%)

133 (67.5%)

 Female

14 (23.7%)

50 (36.2%)

64 (32.5%)

Age, n (%)

0.495^#

  < 60

24 (40.7%)

49 (35.5%)

73 (37.1%)

  ≥ 60 years

35 (59.3%)

89 (64.5%)

124 (62.9%)

Location, n (%)

0.963^#

 Upper

4 (6.78%)

10 (7.25%)

14 (7.11%)

 Middle

44 (74.6%)

99 (71.7%)

143 (72.6%)

 Lower

11 (18.6%)

29 (21.0%)

40 (20.3%)

pThickness (cm)

1.30(1.00–1.75)

1.00 (0.80–1.40)

1.00 (1.00–1.50)

 < 0.001^*

pLength (cm)

4.00 (3.00–5.00)

3.50 (3.00–4.38)

3.50 (3.00–5.00)

0.001^*

PNI, n (%)

0.020^#

 Negative

31 (52.5%)

98 (71.0%)

129 (65.5%)

 Positive

28 (47.5%)

40 (29.0%)

68 (34.5%)

Differentiation grade, n (%)

0.177^&

 I

0 (0.00%)

2 (1.45%)

2 (1.02%)

 II

34 (57.6%)

96 (69.6%)

130 (66.0%)

 III

25 (42.4%)

40 (29.0%)

65 (33.0%)

pT stage, n (%)

 < 0.001^&

 T1

0

12 (8.70%)

12 (6.09%)

 T2

3 (5.08%)

33 (23.9%)

36 (18.3%)

 T3

56 (94.9%)

92 (66.7%)

148 (75.1%)

 T4

0 (0.00%)

1 (0.72%)

1 (0.51%)

pN stage, n (%)

 < 0.001^&

 N0

10 (16.9%)

89 (64.5%)

99 (50.3%)

 N1

21 (35.6%)

32 (23.2%)

53 (26.9%)

 N2

15 (25.4%)

14 (10.1%)

29 (14.7%)

 N3

13 (22.0%)

3 (2.17%)

16 (8.12%)

pAJCC stage, n (%)

 < 0.001^&

 I

0

8 (5.80%)

8 (4.06%)

 II

10 (16.9%)

83 (60.1%)

93 (47.2%)

 III

33 (55.9%)

43 (31.2%)

76 (38.6%)

 IV

16 (27.1%)

4 (2.90%)

20 (10.2%)